Paratek reports SPA deal; Allena garners rights in Althea deal;

 @FierceBiotech: Moscow backs clones of Western biotech programs in Russia. Article | Follow @FierceBiotech

 @JohnCFierce: Merrimack Pharma is scaling back in hopes of finally pulling off an IPO. Now wants $100M. Persistent. Very persistent. More | Follow @JohnCFierce

 @RyanMFierce: Uh oh, Abbott, here come the Humira knockoff makers: More | Follow @RyanMFierce

@FierceMedDev: Biomet had previous run-in with feds | The Journal Gazette | Fort Wayne, IN. Item | Follow @FierceMedDev

> Paratek Pharmaceuticals says it reached agreement with the FDA on its second Special Protocol Assessment related to the Phase III program design for the company's lead antibiotic candidate, omadacycline (formerly PTK 0796). Release

> Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio, including product patents, regulatory information and development data related to oxalate degrading enzymes. Release

> IntelliCell BioSciences says it received a warning letter from the FDA related to an inspection conducted between Nov. 8 and Dec. 12, 2011. Dr. Steven Victor, chairman of IntelliCell Biosciences, said: "The FDA Warning Letter is an opportunity for the company to discuss the observations of the company's facilities relating to current good manufacturing practices (cGMP's) with the FDA." Release

Pharma News

 @FiercePharma: Watson is close to a deal for Actavis, Bloomberg's sources say. Deal could be worth $6B. News | Follow @FiercePharma

> Amylin reportedly stiff-armed $3.5B offer from BMS. More

> Affymax approval breaks Amgen's long anemia monopoly. Story

> Pfizer open to Abbott-style split, analyst says. Article

Medical Device News

> FDA unveils guidance on how PMAs, de novo submissions are reviewed. News

> Strand Diagnostics to receive $30M from Soon-Shiong's NantWorks. Item

> Great Lakes NeuroTechnologies eyes DBS market for Parkinson's. More

> FDA unveils guidance on how PMAs, de novo submissions are reviewed. Article

> Consumer Reports blasts implant safety. Story

Biomarkers News

> The magnetic attraction of blood biomarkers. Article

> DiaGenic, GE combine genes and imaging for AD. Item

> Omics tests need validation. Commentary

> Brain atrophy links with tau biomarker in Alzheimer's progression. More

> Faulty genes may trigger early autistic brain growth. More

Drug Delivery News

> U Miami debuts bionanotech institute with drug delivery agenda. More

> DOD-funded project fuels inner ear drug delivery. Story

> Brazil's FBM Industria licenses Ampio's quick-dissolve premature-ejaculation pill. Article

> Supreme Court upholds Unigene's nasal delivery patent. News

And Finally… Investigators offered fresh support for the notion that red-hot chili peppers could help your heart. Release

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.